12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Interim Phase Ib/II data

Interim data from the open-label, U.S. Phase Ib/II PCYC-1108-CA trial in 30 patients with relapsed or refractory CLL showed that once-daily 420 mg oral PCI-32765 plus bendamustine and rituximab led to an ORR of 90%, with 10% of patients achieving a complete response and 80% achieving a partial response. Additionally, 2 patients achieved a nodal response with residual lymphocytosis. Median follow-up was 4.9 months. Grade 3/4 neutropenia and thrombocytopenia were reported...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >